578 results about "Dry eyes" patented technology

The invention relates to recombinant III-type humanized collagen and application of a composition containing the same to eyes. The invention provides an application of recombinant III type humanized collagen in preparation of a product for preventing and / or treating eye inflammation, a composition containing the recombinant III type humanized collagen, and an application of the composition in preparation of a product for preventing and / or treating eye inflammation and / or eye dryness. The recombinant III-type humanized collagen and the composition containing the recombinant III-type humanized collagen can obviously promote updating and repairing of corneal epithelial cells, and meanwhile, can inhibit release of inflammatory mediators, enhance eye tissue barriers, enhance tear film stability and relieve eye inflammation and eye dryness.

The invention relates to the technical field of artificial intelligence, and discloses a traditional Chinese medicine diabetes dry eye treatment difference evaluation system and method based on artificial intelligence, and the system comprises a four-diagnosis integrated module, a syndrome modeling module, an intelligent decision module, a curative effect feedback module, a knowledge base management module and a self-adaptive learning module. Multi-mode traditional Chinese medicine four-diagnosis data of tongue condition, pulse condition and eye diagnosis and modern physiological parameters of metabolic indexes are fused, a deep learning method is adopted for standardization processing, the problem that traditional Chinese medicine syndrome differentiation depends on subjective experience is solved, traditional Chinese medicine syndrome feature extraction of diabetes dry eye has objectivity and quantifiability, and the traditional Chinese medicine syndrome feature extraction efficiency is improved. The comprehensiveness and the accuracy of the diagnosis basis are improved; and the curative effect feedback module compares a prediction result with revival curative effect data in real time, and the knowledge base management module is linked to carry out case feature matching and strategy optimization, so that continuous optimization and long-term reliability of the treatment decision model are ensured.

The purpose of the present invention is to provide: a novel therapeutic or prophylactic agent for xerophthalmia; a therapeutic or prophylactic agent for graft-versus-host disease; a corneal epithelium wound healing promoter; a corneal invasive inflammatory cell inhibitor; or an inhibitor of differentiation of lymphocytes into effector T cells. The present invention provides: a therapeutic or prophylactic agent for xerophthalmia, a therapeutic or prophylactic agent for graft-versus-host disease, a corneal epithelial wound healing promoter, a corneal invasive inflammatory cell inhibitor, a tear amount maintenance agent, a corneal epithelial damage inhibitor, and a method for preparing the same, which comprises, as an active ingredient, a substance derived from a stem cell culture supernatant; a cell proliferation marker positive cell inhibitor, or an inhibitor of differentiation of lymphocytes to effector T cells.

A dry eye composition containing hypochlorous acid and a demulcent. The demulcent can be polyvinylpyrrolidoe with a molecular weight of 30-50 kDa. The composition can be applied to the surface of the eye with a dropper device or a spray dispenser. Critically, hypochlorous acid is stable in the dry eye composition and maintains its effectiveness at preventing microbial growth.

The utility model relates to the technical field of contact lenses, and particularly discloses a comfortable sclera lens which comprises an outer surface, the inner side of the outer surface is connected with an optical area, the periphery of the optical area is sequentially provided with a first transition area, a second transition area and a landing area, the first transition area and the second transition area are connected with each other, and the optical area is not in contact with the cornea. A plurality of liquid guide grooves are evenly formed in the inner side of the landing area at intervals, the inner ends of the liquid guide grooves penetrate through the first transition area and the second transition area and extend to the edge of the optical area, through holes are formed in the positions, close to the edge of the landing area, of the bottoms of the liquid guide grooves, and the through holes penetrate through the landing area. According to the sclera lens, the plurality of liquid guide grooves are formed, tear exchange between the sclera lens and the periphery of the eyes can be achieved after the sclera lens is worn, the situation that the eyes are dry after the sclera lens is worn for a long time is relieved, meanwhile, the through holes are formed in the inner sides of the liquid guide grooves, the tear exchange efficiency can be further improved through the through holes, the oxygen permeation rate can be improved, and the comfort degree is high when the sclera lens is worn.

The invention discloses an image processing system and method for distinguishing xerophthalmia types, and relates to the technical field of image processing, and the method comprises the steps: firstly carrying out the standardization preprocessing of an original infrared meibomian gland image, further introducing an artifact perception link, and actively recognizing and positioning the interference regions, such as eyelash shielding and uneven illumination, in the image; and guiding the subsequent meibomian gland segmentation process by using the sensed artifact information, thereby realizing the accurate extraction of the meibomian gland form under the complex background. On the basis, multi-dimensional quantification is carried out on the precisely segmented gland form, and image features are converted into objective numerical indexes. And finally, carrying out comprehensive judgment on the numerical indexes by utilizing a decision tree model, and outputting standardized MGD severity grade. In this way, interference information brought by image artifacts can be intelligently suppressed, and therefore more robust and accurate MGD severity grading is achieved in a clinical image with poor quality.

The invention relates to the field of biological medicine, in particular to a carrier-free nanoparticle which is formed by self-assembly of cyclosporine A and costunolide through intermolecular weak interaction. The invention also provides a preparation method of the traditional Chinese medicine composition and application of the traditional Chinese medicine composition in preparation of medicines for treating xerophthalmia. The carrier-free nano eye drops based on the synergistic effect of Chinese and western medicines are used for anti-inflammatory treatment of the xerophthalmia, a new strategy is provided for precise diagnosis and treatment of the xerophthalmia, the problems of single target spot, limited curative effect and the like in traditional treatment are solved, and more efficient inflammation control is expected to be achieved. While the curative effect is improved, the tolerance risk caused by long-term use is reduced, double optimization of the curative effect and safety is realized, and the limitation of traditional single drug treatment is broken through. By adopting the carrier-free nano preparation, the delivery efficiency of the medicine on the ocular surface is effectively improved, the bioavailability is enhanced, powerful support is provided for improving the curative effect of the medicine, and the carrier limitation bottleneck is broken through.

The invention discloses a dry eye disease course supervision and prediction method and system based on AI image recognition, and relates to the technical field of medical image processing, and the method comprises the steps: obtaining blink behavior video data, meibomian gland infrared imaging data and time sequence ocular surface microvessel image data; analyzing the blink behavior video data, and extracting blink feature data; performing image processing on the infrared imaging data of the meibomian glands, and extracting feature data of the meibomian glands; carrying out binarization and thinning processing on the sequential ocular surface microvascular image data, and extracting blood vessel feature data; standardizing the blood vessel feature data, and fusing to generate a comprehensive feature vector; inputting the comprehensive feature vector into a classification model, and judging a dry eye disease course stage; executing trend analysis based on historical data of the comprehensive feature vector, and generating prediction data and intervention suggestion data; the method has the beneficial effects that through multi-modal image data fusion analysis, accurate monitoring and prediction of the xerophthalmia course are realized, and a scientific basis is provided for clinical intervention.

The present invention relates generally to compositions, formulations, and methods for immunotherapy and drug delivery, including the treatment of eye diseases such as dry eye disease (DED). In particular, the present invention relates to methods of producing exosomes from mesenchymal stem cells (MSC-Exos) and, optionally, loading said exosomes with one or more bioactive substances. The exosomes may be loaded using electroporation with one or more bioactive substances such as proteins, miRNAs, and / or siRNA. In specific embodiments, the exosomes, and / or one or more biological compounds derived from the exosomes, may be provided to an individual in need thereof, including as part of one or more compositions containing mesenchymal stem cells (MSCs). The individual in need thereof may be an individual having a medical disorder such as DED, immune disorders, cancer, and other disorders. Therefore, the compositions containing MSCs can be used for topical application to the eye. The compositions can contain MSCs, MSC-Exos, one or more MSC-derived biological compounds (e.g., growth factors, proteins, etc.).

The present invention provides formulations of 4-(7-hydroxy-2-isopropyl-4-oxo-4H-quinazolin-3-yl)-benzonitrile (compound I) and methods for treating ocular surface pain by administering such formulations. The present invention also provides methods for treating dry eye disease and ocular hyperemia by administering formulations of 4-(7-hydroxy-2-isopropyl-4-oxo-4H-quinazolin-3-yl)-benzonitrile.

Described herein are methods and pharmaceutical formulations for treating dry eye disease.

The invention provides an eye drop composition as well as a preparation method and application thereof, and belongs to the technical field of ophthalmic preparations. The eye drop composition adopted by the invention is prepared from the following components: brimonidine tartrate, hyaluronic acid, collagen, trehalose and injection water. By compounding the components, the eye drops which can realize slow release of brimonidine tartrate and prolong the antihypertensive action time and have the characteristics of relieving blink discomfort, long-acting moisturizing, anti-inflammatory soothing, mildness, corrosion prevention and the like are prepared; the eye drops are beneficial to people suffering from glaucoma, intraocular hypertension, xerophthalmia, postoperative inflammation or allergy and preservative sensitivity or preservative allergy, the life quality is improved, and diseases are relieved.

In one aspect, a computerized method includes the step of obtaining a set of eye data of a patient from a medical practitioner in a computer input form. The method includes the step of acquiring a set of dry eye patient data from a set of well-structured dry eye patient data samples, wherein each sample dry eye patient data comprises a plurality of features. The method includes the step of identifying the plurality of data features in the set of well-structured dry eye patient data samples. The method includes the step of implementing a data cleaning process on the set of well-structured dry eye patient data samples. The method includes the step of implementing a feature selection on the set of well-structured dry eye patient data samples, wherein the feature selection comprises selecting a subset of relevant features for machine-learning model construction. The method includes the step of providing a specified machine-learning (ML) model. The method includes the step of training the ML model with the set of well-structured dry eye patient data samples. The method includes the step of validating the ML model with the set of well-structured dry eye patient data samples. The method includes the step of providing the set of eye data of the patient to the trained and validated ML model. With the trained and validated ML model, the method includes the step of classifying the set of eye data of the patient as a dry eye category and a dry eye type.

According to the xerophthalmia core index multi-task AI detection system, method and terminal provided by the invention, the xerophthalmia multi-modal image is collected and exclusive preprocessing is completed, and core index detection is carried out on the preprocessed image based on the xerophthalmia multi-index detection model, so that the xerophthalmia core index detection result is obtained. Outputting detection results such as meibomian gland deletion rate, tear film rupture time, staining classification, tear river height and blepharitis marginal inflammation classification; and dynamically adjusting the index result according to a calibration coefficient corresponding to the type of the data acquisition equipment, and finally generating a standardized detection report. A xerophthalmia multi-index detection model is constructed based on an improved U-Net3 + architecture, a dry eye feature enhancement encoder and a cross-scale feature fusion decoder are adopted, a customized multi-task detection head is matched, an inter-task attention collaboration mechanism is established, meanwhile, a preprocessing algorithm and a dynamic calibration mechanism matched with a dry eye image are designed, and the detection accuracy of the xerophthalmia is improved. And multi-index synchronous, high-precision and high-efficiency detection is effectively realized.

The present invention relates to pharmaceutical composition comprising combination of Lifitegrast and Loteprednol etabonate along with one or more pharmaceutically acceptable excipients for the treatment of dry eye disease.

The invention provides pharmaceutical compositions comprising about 0.05 to 0.1% (w / v) cyclosporine dissolved in 1-perfluorobutyl-pentane for use in the topical treatment of dry eye disease and provides for dosing and treatment methods thereof. The invention further provides kits comprising such compositions.

The present invention discloses a traditional Chinese medicine composition for treating dry eye and a preparation method thereof. The traditional Chinese medicine composition for treating dry eye is made from the following components in parts by weight: 10-12 parts of Chinese wolfberry, 5-10 parts of chrysanthemum, 10-15 parts of cassia seed, 10-12 parts of cortex fraxini, 5-10 parts of safflower, and 10-12 parts of phellodendron amurense. The traditional Chinese medicine composition for treating dry eye prepared by this method has less dosage, is convenient to use, safe and without side effects when treating dry eye, and has a significant therapeutic effect in aspects such as prolonging the breakup of the tear film, increasing the tear flow rate, and improving corneal staining, and can be promoted as a drug for treating dry eye.

Dry eye treatment apparatus and methods are described herein which generally comprise a patch or strip affixed to the skin of the upper and / or lower eyelids to deliver heat or other forms of energy, pressure, drugs, moisture, etc. (alone or in combination) to the one or more meibomian glands contained within the underlying skin. The treatment strip or strips include one or more strips configured to adhere to an underlying region of skin in proximity to one or both eyes of a subject such that the one or more strips allow for the subject to blink naturally without restriction from the one or more patches. Moreover, the one or more strips may be configured to emit energy to the underlying region of skin and where the one or more strips are shaped to follow a location of one or more meibomiam glands contained within the underlying region of skin.

The invention features ALK2 antibodies and antigen binding fragments thereof (e.g., ALK2 binding fragments). The invention also features pharmaceutical compositions and methods of using the ALK2 antibodies or antigen binding fragments thereof to treat bone disease or damage, low red blood cell levels (e.g., anemia or blood loss), heterotopic ossification (e.g., heterotopic ossification resulting from fibrodysplasia ossificans progressiva), Sjogren's syndrome (e.g., dry eye associated with Sjogren's syndrome), multiple osteochondroma, diffuse intrinsic pontine glioma, posterior capsule opacification, or cardiac hypertrophy and / or cardiac fibrosis.

The invention belongs to the technical field of artificial intelligence, and discloses a dry eye diagnosis and treatment integrated system based on a deep neural network, which comprises an input unit module, a diagnosis unit module, a data matching module and an output unit module, and is characterized in that dry eye symptoms and OSDI scale result characteristics of a patient to be diagnosed are input through the input unit module; the diagnosis unit module obtains the dry eye symptom, the OSDI scale and the corresponding relation between the lower tear river height and the mild dryness, moderate dryness and severe dryness of a patient, the data matching module matches the result features of the dry eye symptom, the OSDI scale and the psychological survey scale of the patient to be diagnosed into the corresponding relation, and a corresponding matching diagnosis report is generated. And finally, outputting grading diagnosis of light, moderate and heavy dry eyes of the patient to be diagnosed through an output unit module. The system can help clinicians to improve the diagnosis efficiency of dry eye grading and reduce missed diagnosis and misdiagnosis, and is high in operability.

Provided is a dry eye therapeutic agent that can selectively inhibit IFN-y, have no risk of biological contamination, and can be stored at room temperature. Provided is a dry eye therapeutic agent, comprising as an active ingredient a DNA oligonucleotide having a nucleotide sequence set forth in any of SEQ ID NO:1 to 3 and selectively binding to IFN-y. A base, X, in the sequence of the DNA oligonucleotide having the nucleotide sequence set forth in SEQ ID NO: 3 is an artificially produced base, and the artificially produced base may be chemically modified with a low-molecular-weight compound, a medium-molecular-weight compound, a large-molecular-weight compound, a biopolymer, or a biocompatible polymer.

The invention discloses a ferroptosis inhibition research method based on a hypertonic dry eye cell model, and relates to the technical field of xerophthalmia. Comprising the following steps: S1, establishing a hypertonic dry eye cell model, and selecting human corneal epithelial cells to perform hypertonic treatment in a hypertonic culture medium; s2, detecting a ferroptosis marker; performing GPX4 protein expression detection; s2.1, detecting the lipid peroxidation level; s2.2, detecting the iron ion level of the sample; s2.3, observing the mitochondrial morphology of the sample; s3, carrying out an autoserum intervention experiment, and treating the culture media of different groups by using autoserum; s4, data statistics and analysis; by detecting expression of proteins such as a ferroptosis marker GPX4 and the like, it is determined that autoserum can inhibit ferroptosis and improve corneal epithelial cell survival by enhancing GPX4 expression and reducing lipid peroxidation and iron ion level, a scientific basis is provided for further optimization and accurate application, a treatment strategy for xerophthalmia is improved, and the application has a wide application prospect. And a new direction is opened up for mechanism research and personalized treatment of the xerophthalmia in the future.

Described herein are methods and pharmaceutical formulations for treating dry eye disease.

A dry eye treatment device, having a roller, a holder, wherein the roller contacts and rolls over an eyelid in a plurality of directions in a treatment; a heating element to generate heat, wherein at least a portion of the heat is transferred to the roller; a temperature monitoring system, which has a thermal sensor and a temperature control circuit; and an electric power source. The roller is of a convex cylindrical or concave cylindrical shape. A method for dry eye treatment, of cleaning an eyelid with a first cleansing wipe; heating a roller to a predetermined temperature; applying thermally conductive gel between the roller and the eyelid; rolling the roller over the eyelid in a plurality of directions; and removing the thermally conductive gel and expressed debris with a second cleansing wipe; and further, increasing the temperature by an increment and repeating the treatment method.

The invention belongs to the technical field of traditional Chinese medicines, and particularly relates to a traditional Chinese medicine composition for relieving asthenopia and a preparation method and application thereof. The traditional Chinese medicine composition is prepared from the following raw material medicines in parts by weight: 1-20 parts of schisandra chinensis, 1-20 parts of dogwood, 1-20 parts of rhizoma polygonati, 1-15 parts of glossy privet fruit, 1-15 parts of bighead atractylodes rhizome, 1-10 parts of white mulberry root-bark and 1-10 parts of chrysanthemum. The invention further provides a preparation method of the traditional Chinese medicine composition and application of the traditional Chinese medicine composition in preparation of drugs for relieving asthenopia. The traditional Chinese medicine composition disclosed by the invention has an obvious effect on the symptoms of dim vision, dry eyes, eye distension and eye and eye socket ache caused by asthenopia.

Dry eye treatment apparatus and methods which include one or more patches or strips affixed to the skin of the upper and / or lower eyelids to deliver heat or other forms of energy, pressure, drugs, moisture, etc. (alone or in combination) to the one or more meibomian glands contained within the underlying skin. The one or more patches or strips may allow for the subject to blink naturally without restriction from the one or more patches or strips. The one or more patches or strips may be shaped to follow a location of one or more meibomiam glands contained within the underlying region of skin.

Controllers for dry eye treatment apparatus and methods are described herein which generally comprise a patch or strip affixed to the skin of the upper and / or lower eyelids to deliver heat to the one or more meibomian glands contained within the underlying skin. The treatment strip or strips include one or more strips configured to adhere to an underlying region of skin in proximity to one or both eyes of a subject such that the one or more strips allow for the subject to blink naturally without restriction from the one or more patches. A controller is in communication with the one or more strips and is programmable to monitor a temperature of the one or more strips to provide a treatment therapy above a threshold temperature of, e.g., 39° C., and below a maximum temperature of, e.g., 48° C., over a treatment period of 12 minutes.

In some aspects, an electronic contact lens for treating dry eye is presented. According to some aspects, the electronic contact lens includes a concave surface configured to conform to an eye of a patient, a sensor configured to generate a signal indicative of an eyelid movement, and at least one capacitor configured to store energy used for stimulating the eye. The electronic contact lens may further include at least two electrodes coupled to the at least one capacitor, wherein the at least two electrodes are exposed to the concave surface and configured to deliver power from the at least one capacitor to stimulate the eye. The electronic contact lens further includes a processor coupled to the sensor and electrodes. The processor may be configured to compute a blink rate from the sensor output, and, based on the blink rate, activate the at least two electrodes to stimulate the eye.

The invention discloses pranoprofen temperature-sensitive gel for treating xerophthalmia and a preparation method, the gel takes poloxamer 407 and poloxamer 188 as matrixes, the optimal ratio of the poloxamer 407 to the poloxamer 188 is 23.5%: 2%, and the ratio is optimized and determined by a central composite design-response surface method. During preparation, a blank gel solution is prepared firstly, and then auxiliary materials such as pranoprofen and the like are added for dissolution. The in-vitro release characteristic is good, the accumulated dissolution rate within 210 min exceeds 90%, and the zero-level pharmacokinetic process is achieved. An SD rat xerophthalmia model is established, and it is proved that the xerophthalmia treatment effect of the composition is better than that of eye drops. In eye tissue distribution and aqueous humor pharmacokinetic studies, higher target organ distribution characteristics are shown, the aqueous humor AUC0-t is 1.85 times that of eye drops, and the bioavailability is high. The invention further provides a gel preparation method, a drug effect evaluation method and a related research method, and a new effective dosage form and a new treatment thought are provided for xerophthalmia treatment.

The invention belongs to the technical field of compositions, and provides a moisture-retaining and eye-moistening composition as well as a preparation method and application thereof. According to the moisturizing eye-moistening composition provided by the invention, the soybean lecithin, the retinol palmitate lipidosome, the xanthophyll, the oligomeric hyaluronic acid and the ethylenediamine tetraacetic acid in a specific ratio are combined, and all the components can play a good synergistic effect, so that the effects of relieving asthenopia symptoms, protecting eyesight and maintaining normal vision are improved; the eye drops can improve and relieve eye dryness and eye astringency symptoms caused by various reasons (such as fatigue, wearing of contact lenses, use of electronic products, excessive use of eyes and the like).